Review of MOA and Effectiveness of Current Treatments
Hematologic oncologists review therapeutic options for patients with chronic GVHD and provide clinical insights on their treatment approaches.
Video content above is prompted by the following questions:
- Please discuss the effectiveness of the most used systemic treatment options.
- How do you sequence treatments for chronic GVHD?
- What are the most pressing challenges faced by healthcare providers in effectively managing cGVHD, particularly in patients who have progressed through multiple treatment lines?
COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS
October 23rd 2024During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
